熱門資訊> 正文
SciSparc宣布公布日本专利申请
2025-05-27 20:46
- SciSparc (NASDAQ:SPRC) has announced the publication of a Japanese divisional patent.
- The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy.
- By working synergistically, the combination may reduce the required paracetamol dose, minimizing risks like liver damage while improving outcomes for acute, chronic, and neuropathic pain, as well as fever.
- “This patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common drug,” said Oz Adler, CEO of SciSparc.
More on SciSparc
- SciSparc to sell MitoCareX to N2Off for $700,000
- Financial information for SciSparc Ltd.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
